ID   MAG_MOUSE               Reviewed;         627 AA.
AC   P20917; A0A087WPR1; P16880;
DT   01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT   18-SEP-2019, sequence version 3.
DT   03-AUG-2022, entry version 200.
DE   RecName: Full=Myelin-associated glycoprotein;
DE   AltName: Full=Siglec-4a;
DE   Flags: Precursor;
GN   Name=Mag;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS L-MAG AND S-MAG).
RX   PubMed=2482022; DOI=10.1016/0006-291x(89)92724-1;
RA   Fujita N., Sato S., Kurihara T., Kuwano R., Sakimura K., Inuzuka T.,
RA   Takahashi Y., Miyatake T.;
RT   "cDNA cloning of mouse myelin-associated glycoprotein: a novel alternative
RT   splicing pattern.";
RL   Biochem. Biophys. Res. Commun. 165:1162-1169(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM S-MAG).
RC   TISSUE=Brain;
RX   PubMed=1712586; DOI=10.1016/0006-291x(91)91811-p;
RA   Nakano R., Fujita N., Sato S., Inuzuka T., Sakimura K., Ishiguro H.,
RA   Mishina M., Miyatake T.;
RT   "Structure of mouse myelin-associated glycoprotein gene.";
RL   Biochem. Biophys. Res. Commun. 178:282-290(1991).
RN   [3] {ECO:0000312|Proteomes:UP000000589}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=C57BL/6J {ECO:0000312|Proteomes:UP000000589};
RX   PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
RA   Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S., She X.,
RA   Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W., Kapustin Y.,
RA   Meric P., Maglott D., Birtle Z., Marques A.C., Graves T., Zhou S.,
RA   Teague B., Potamousis K., Churas C., Place M., Herschleb J., Runnheim R.,
RA   Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z., Lindblad-Toh K.,
RA   Eichler E.E., Ponting C.P.;
RT   "Lineage-specific biology revealed by a finished genome assembly of the
RT   mouse.";
RL   PLoS Biol. 7:E1000112-E1000112(2009).
RN   [4]
RP   PROTEIN SEQUENCE OF 78-88 AND 466-477, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   STRAIN=C57BL/6J; TISSUE=Brain;
RA   Lubec G., Kang S.U.;
RL   Submitted (APR-2007) to UniProtKB.
RN   [5]
RP   TISSUE SPECIFICITY.
RX   PubMed=2474006; DOI=10.1002/cne.902840310;
RA   Bartsch U., Kirchhoff F., Schachner M.;
RT   "Immunohistological localization of the adhesion molecules L1, N-CAM, and
RT   MAG in the developing and adult optic nerve of mice.";
RL   J. Comp. Neurol. 284:451-462(1989).
RN   [6]
RP   TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, AND GLYCOSYLATION.
RX   PubMed=1716323; DOI=10.1002/jnr.490290202;
RA   Pedraza L., Frey A.B., Hempstead B.L., Colman D.R., Salzer J.L.;
RT   "Differential expression of MAG isoforms during development.";
RL   J. Neurosci. Res. 29:141-148(1991).
RN   [7]
RP   FUNCTION, SIALIC ACID-BINDING, SUBCELLULAR LOCATION, AND TOPOLOGY.
RX   PubMed=7533044; DOI=10.1016/s0960-9822(00)00220-7;
RA   Kelm S., Pelz A., Schauer R., Filbin M.T., Tang S., de Bellard M.E.,
RA   Schnaar R.L., Mahoney J.A., Hartnell A., Bradfield P., Crocker P.R.;
RT   "Sialoadhesin, myelin-associated glycoprotein and CD22 define a new family
RT   of sialic acid-dependent adhesion molecules of the immunoglobulin
RT   superfamily.";
RL   Curr. Biol. 4:965-972(1994).
RN   [8]
RP   DISRUPTION PHENOTYPE, FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=7516497; DOI=10.1038/369747a0;
RA   Li C., Tropak M.B., Gerlai R., Clapoff S., Abramow-Newerly W., Trapp B.,
RA   Peterson A., Roder J.;
RT   "Myelination in the absence of myelin-associated glycoprotein.";
RL   Nature 369:747-750(1994).
RN   [9]
RP   DISRUPTION PHENOTYPE, AND FUNCTION.
RX   PubMed=9262180; DOI=10.1016/s0006-8993(97)00484-8;
RA   Bartsch S., Montag D., Schachner M., Bartsch U.;
RT   "Increased number of unmyelinated axons in optic nerves of adult mice
RT   deficient in the myelin-associated glycoprotein (MAG).";
RL   Brain Res. 762:231-234(1997).
RN   [10]
RP   DISRUPTION PHENOTYPE, AND FUNCTION.
RX   PubMed=9482781; DOI=10.1523/jneurosci.18-06-01953.1998;
RA   Yin X., Crawford T.O., Griffin J.W., Tu P.-H., Lee V.M., Li C., Roder J.,
RA   Trapp B.D.;
RT   "Myelin-associated glycoprotein is a myelin signal that modulates the
RT   caliber of myelinated axons.";
RL   J. Neurosci. 18:1953-1962(1998).
RN   [11]
RP   FUNCTION (ISOFORM L-MAG), TISSUE SPECIFICITY, SUBCELLULAR LOCATION,
RP   TOPOLOGY, AND DOMAIN.
RX   PubMed=9482783; DOI=10.1523/jneurosci.18-06-01970.1998;
RA   Fujita N., Kemper A., Dupree J., Nakayasu H., Bartsch U., Schachner M.,
RA   Maeda N., Suzuki K., Popko B.;
RT   "The cytoplasmic domain of the large myelin-associated glycoprotein isoform
RT   is needed for proper CNS but not peripheral nervous system myelination.";
RL   J. Neurosci. 18:1970-1978(1998).
RN   [12]
RP   DISRUPTION PHENOTYPE, AND FUNCTION.
RX   PubMed=9469574;
RX   DOI=10.1002/(sici)1097-4547(19980115)51:2<210::aid-jnr9>3.0.co;2-g;
RA   Li C., Trapp B., Ludwin S., Peterson A., Roder J.;
RT   "Myelin associated glycoprotein modulates glia-axon contact in vivo.";
RL   J. Neurosci. Res. 51:210-217(1998).
RN   [13]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=10625334;
RX   DOI=10.1002/(sici)1098-1136(20000115)29:2<154::aid-glia9>3.0.co;2-3;
RA   Schachner M., Bartsch U.;
RT   "Multiple functions of the myelin-associated glycoprotein MAG (siglec-4a)
RT   in formation and maintenance of myelin.";
RL   Glia 29:154-165(2000).
RN   [14]
RP   FUNCTION, AND INTERACTION WITH RTN4R.
RX   PubMed=12089450; DOI=10.1126/science.1073031;
RA   Liu B.P., Fournier A., GrandPre T., Strittmatter S.M.;
RT   "Myelin-associated glycoprotein as a functional ligand for the Nogo-66
RT   receptor.";
RL   Science 297:1190-1193(2002).
RN   [15]
RP   INTERACTION WITH BSG.
RX   PubMed=12558975; DOI=10.1046/j.1471-4159.2003.01537.x;
RA   Heller M., von der Ohe M., Kleene R., Mohajeri M.H., Schachner M.;
RT   "The immunoglobulin-superfamily molecule basigin is a binding protein for
RT   oligomannosidic carbohydrates: an anti-idiotypic approach.";
RL   J. Neurochem. 84:557-565(2003).
RN   [16]
RP   DISRUPTION PHENOTYPE, AND FUNCTION.
RX   PubMed=15953602; DOI=10.1016/j.expneurol.2005.04.017;
RA   Pan B., Fromholt S.E., Hess E.J., Crawford T.O., Griffin J.W., Sheikh K.A.,
RA   Schnaar R.L.;
RT   "Myelin-associated glycoprotein and complementary axonal ligands,
RT   gangliosides, mediate axon stability in the CNS and PNS: neuropathology and
RT   behavioral deficits in single- and double-null mice.";
RL   Exp. Neurol. 195:208-217(2005).
RN   [17]
RP   FUNCTION.
RX   PubMed=17640868; DOI=10.1074/jbc.m704055200;
RA   Mehta N.R., Lopez P.H., Vyas A.A., Schnaar R.L.;
RT   "Gangliosides and Nogo receptors independently mediate myelin-associated
RT   glycoprotein inhibition of neurite outgrowth in different nerve cells.";
RL   J. Biol. Chem. 282:27875-27886(2007).
RN   [18]
RP   DISRUPTION PHENOTYPE, FUNCTION, DOMAIN, AND MUTAGENESIS OF
RP   118-ARG--ASP-120.
RX   PubMed=19158290; DOI=10.1523/jneurosci.5204-08.2009;
RA   Nguyen T., Mehta N.R., Conant K., Kim K.J., Jones M., Calabresi P.A.,
RA   Melli G., Hoke A., Schnaar R.L., Ming G.L., Song H., Keswani S.C.,
RA   Griffin J.W.;
RT   "Axonal protective effects of the myelin-associated glycoprotein.";
RL   J. Neurosci. 29:630-637(2009).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-591, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and expression.";
RL   Cell 143:1174-1189(2010).
RN   [20]
RP   TISSUE SPECIFICITY, AND UBIQUITINATION.
RX   PubMed=24191038; DOI=10.1073/pnas.1318501110;
RA   Shin D., Lin S.T., Fu Y.H., Ptacek L.J.;
RT   "Very large G protein-coupled receptor 1 regulates myelin-associated
RT   glycoprotein via Galphas/Galphaq-mediated protein kinases A/C.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:19101-19106(2013).
RN   [21]
RP   DISRUPTION PHENOTYPE, FUNCTION, DOMAIN, AND INTERACTION WITH RTN4R AND
RP   RTN4RL2.
RX   PubMed=26335717; DOI=10.1038/cddis.2015.228;
RA   Palandri A., Salvador V.R., Wojnacki J., Vivinetto A.L., Schnaar R.L.,
RA   Lopez P.H.;
RT   "Myelin-associated glycoprotein modulates apoptosis of motoneurons during
RT   early postnatal development via NgR/p75(NTR) receptor-mediated activation
RT   of RhoA signaling pathways.";
RL   Cell Death Dis. 6:E1876-E1876(2015).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.12 ANGSTROMS) OF 20-325, X-RAY CRYSTALLOGRAPHY
RP   (3.80 ANGSTROMS) OF 20-508 IN COMPLEX WITH
RP   N-ACETYLNEURAMINYL-N-ACETYLLACTOSAMINE, FUNCTION, DISULFIDE BONDS,
RP   GLYCOSYLATION AT TRP-22; ASN-99; ASN-223; ASN-246; ASN-315; ASN-332;
RP   ASN-406; ASN-450 AND ASN-454, IDENTIFICATION BY MASS SPECTROMETRY, SUBUNIT,
RP   AND MUTAGENESIS OF TRP-25; TYR-65; ARG-118; TYR-127; THR-128; ASN-406 AND
RP   ILE-473.
RX   PubMed=27922006; DOI=10.1038/ncomms13584;
RA   Pronker M.F., Lemstra S., Snijder J., Heck A.J., Thies-Weesie D.M.,
RA   Pasterkamp R.J., Janssen B.J.;
RT   "Structural basis of myelin-associated glycoprotein adhesion and
RT   signalling.";
RL   Nat. Commun. 7:13584-13584(2016).
CC   -!- FUNCTION: Adhesion molecule that mediates interactions between
CC       myelinating cells and neurons by binding to neuronal sialic acid-
CC       containing gangliosides and to the glycoproteins RTN4R and RTN4RL2
CC       (PubMed:7533044, PubMed:12089450, PubMed:27922006). Not required for
CC       initial myelination, but seems to play a role in the maintenance of
CC       normal axon myelination (PubMed:7516497, PubMed:9262180,
CC       PubMed:9482781, PubMed:9482783, PubMed:9469574, PubMed:10625334).
CC       Protects motoneurons against apoptosis, also after injury; protection
CC       against apoptosis is probably mediated via interaction with neuronal
CC       RTN4R and RTN4RL2 (PubMed:26335717). Required to prevent degeneration
CC       of myelinated axons in adults; this probably depends on binding to
CC       gangliosides on the axon cell membrane (PubMed:15953602,
CC       PubMed:19158290). Negative regulator of neurite outgrowth that inhibits
CC       axon longitudinal growth (PubMed:19158290, PubMed:27922006,
CC       PubMed:12089450). Negative regulator of neurite outgrowth; in dorsal
CC       root ganglion neurons the inhibition is mediated primarily via binding
CC       to neuronal RTN4R or RTN4RL2 and to a lesser degree via binding to
CC       neuronal gangliosides (PubMed:17640868). In cerebellar granule cells
CC       the inhibition is mediated via binding to neuronal gangliosides
CC       (PubMed:17640868). In sensory neurons, inhibition of neurite extension
CC       depends only partially on RTN4R, RTN4RL2 and gangliosides (By
CC       similarity). Inhibits axon outgrowth by binding to RTN4R
CC       (PubMed:12089450). Preferentially binds to alpha-2,3-linked sialic acid
CC       (PubMed:7533044, PubMed:27922006). Binds ganglioside Gt1b
CC       (PubMed:27922006). {ECO:0000250|UniProtKB:P07722,
CC       ECO:0000269|PubMed:10625334, ECO:0000269|PubMed:12089450,
CC       ECO:0000269|PubMed:15953602, ECO:0000269|PubMed:17640868,
CC       ECO:0000269|PubMed:19158290, ECO:0000269|PubMed:26335717,
CC       ECO:0000269|PubMed:27922006, ECO:0000269|PubMed:7516497,
CC       ECO:0000269|PubMed:7533044, ECO:0000269|PubMed:9262180,
CC       ECO:0000269|PubMed:9469574, ECO:0000269|PubMed:9482781,
CC       ECO:0000269|PubMed:9482783}.
CC   -!- SUBUNIT: Monomer and homodimer (PubMed:27922006). Interacts (via the
CC       first three N-terminal Ig-like domains) with RTN4R and RTN4RL2
CC       (PubMed:12089450, PubMed:26335717). Interacts with isoform 2 of BSG
CC       (PubMed:12558975). {ECO:0000269|PubMed:12089450,
CC       ECO:0000269|PubMed:12558975, ECO:0000269|PubMed:26335717,
CC       ECO:0000269|PubMed:27922006}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:7533044,
CC       ECO:0000269|PubMed:9482783}; Single-pass type I membrane protein
CC       {ECO:0000269|PubMed:7533044, ECO:0000269|PubMed:9482783}. Membrane raft
CC       {ECO:0000250|UniProtKB:P07722}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=L-MAG;
CC         IsoId=P20917-1; Sequence=Displayed;
CC       Name=S-MAG;
CC         IsoId=P20917-2; Sequence=VSP_002527, VSP_002528;
CC   -!- TISSUE SPECIFICITY: Detected in the myelin tract in brain, especially
CC       in the corpus callosum and in peripheral nerve (PubMed:7516497,
CC       PubMed:9482783, PubMed:24191038). Expressed by myelinating glial cells
CC       in the central and peripheral nervous system (PubMed:10625334).
CC       Detected in oligodendrocyte processes before formation of compact
CC       myelin (PubMed:2474006, PubMed:10625334). Restricted to the periaxonal
CC       space after myelination (PubMed:10625334). Isoform S-MAG is the
CC       predominant isoform in CNS and PNS of the adult (at protein level)
CC       (PubMed:1716323). {ECO:0000269|PubMed:10625334,
CC       ECO:0000269|PubMed:1716323, ECO:0000269|PubMed:24191038,
CC       ECO:0000269|PubMed:2474006, ECO:0000269|PubMed:7516497,
CC       ECO:0000269|PubMed:9482783}.
CC   -!- DEVELOPMENTAL STAGE: In CNS isoform L-MAG is the major form synthesized
CC       early in development, and it persists as a significant proportion of
CC       the MAG present in the adult. In the PNS isoform L-MAG is expressed at
CC       modest levels during development; it is absent in the adult.
CC       {ECO:0000269|PubMed:1716323}.
CC   -!- DOMAIN: The C-terminal cytoplasmic region found only in isoform L-MAG
CC       is required for normal myelination in the central nervous system (CNS),
CC       but is apparently not required for normal myelination in the peripheral
CC       nervous system (PNS). {ECO:0000269|PubMed:9482783}.
CC   -!- DOMAIN: The extracellular domain is required to protect against axon
CC       degeneration (PubMed:19158290, PubMed:26335717). The first three Ig-
CC       like domains mediate interaction with RTN4R and RTN4RL2, but are not
CC       sufficient to inhibit neurite outgrowth (By similarity). The two C-
CC       terminal extracellular Ig-like C2-type domains are required for
CC       inhibition of axon longitudinal growth. Besides, the two C-terminal
CC       extracellular Ig-like C2-type domains are required for protection
CC       against apoptosis after nerve injury (PubMed:26335717).
CC       {ECO:0000250|UniProtKB:P07722, ECO:0000269|PubMed:19158290,
CC       ECO:0000269|PubMed:26335717}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:1716323,
CC       ECO:0000269|PubMed:27922006}.
CC   -!- PTM: Phosphorylated on tyrosine residues.
CC       {ECO:0000250|UniProtKB:P07722}.
CC   -!- PTM: Ubiquitinated, leading to proteasomal degradation.
CC       {ECO:0000269|PubMed:24191038}.
CC   -!- DISRUPTION PHENOTYPE: Mutant mice appear normal, excepting subtle
CC       defects in motor coordination and a slight intention tremor
CC       (PubMed:7516497). They have similar numbers of motoneurons as wild-type
CC       at birth, but display an important loss of motoneurons during the first
CC       week after birth (PubMed:26335717).Five month old mutant mice display a
CC       decreased ability to remain on a rotating cylinder (PubMed:15953602).
CC       Contrary to wild-type, about 40% of mutant mice have severe episodes of
CC       whole-body tremor, both during movement and when resting
CC       (PubMed:15953602). The myelination in brain and around peripheral
CC       nerves appears grossly normal in young animals, but the periaxonal
CC       cytoplasmic collar is often missing in optic nerve (PubMed:7516497,
CC       PubMed:9262180, PubMed:9482781, PubMed:9469574). When present, the
CC       cytoplasm of the periaxonal collar has generally a disorganized aspect
CC       (PubMed:7516497). Mutant mice have an increased percentage of
CC       unmyelinated axons in optic nerve (PubMed:9262180, PubMed:9469574).
CC       Besides, a small proportion of nerves from mutant mice display
CC       redundant myelination, and also rare cases of multiple myelination,
CC       where axons are surrounded by two or more compact myelin sheets
CC       (PubMed:9469574). Sciatic nerves from over three month old mutant mice
CC       show signs of Wallerian degeneration, with redundant myelin,
CC       degeneration of myelinated fibers, and an apparent decrease in the
CC       diameter of myelinated axons (PubMed:9482781, PubMed:15953602). The
CC       distances between neurofilaments in myelinated axons from over 3 month
CC       old mice are shorter than normal (PubMed:9482781, PubMed:15953602).
CC       With increasing age, mutant mice display progressive axon degeneration
CC       in the spinal cord and sciatic nerve, resulting in a decrease of 28% in
CC       the number of spinal cord axons after 15 months (PubMed:19158290).
CC       Mutant mice display increased motoneuron apoptosis after injury
CC       (PubMed:26335717). Likewise, they display strongly increased axon
CC       degeneration after treatment with the neurotoxin acrylamide
CC       (PubMed:19158290). Mutant mice display much more severe axon loss in
CC       response to experimental autoimmune encephalitis (PubMed:19158290).
CC       {ECO:0000269|PubMed:15953602, ECO:0000269|PubMed:19158290,
CC       ECO:0000269|PubMed:26335717, ECO:0000269|PubMed:7516497,
CC       ECO:0000269|PubMed:9262180, ECO:0000269|PubMed:9469574,
CC       ECO:0000269|PubMed:9482781}.
CC   -!- SIMILARITY: Belongs to the immunoglobulin superfamily. SIGLEC (sialic
CC       acid binding Ig-like lectin) family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Functional Glycomics Gateway - Glycan Binding;
CC       Note=Siglec-4;
CC       URL="http://www.functionalglycomics.org/glycomics/GBPServlet?&operationType=view&cbpId=cbp_mou_Itlect_196";
CC   -!- WEB RESOURCE: Name=Functional Glycomics Gateway - Glycan Binding;
CC       Note=Siglec-4a [3 Fc Domains];
CC       URL="http://www.functionalglycomics.org/glycomics/GBPServlet?&operationType=view&cbpId=cbp_mou_Itlect_00003";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M31811; AAA39487.1; -; mRNA.
DR   EMBL; M74793; AAA91743.1; -; Genomic_DNA.
DR   EMBL; M74783; AAA91743.1; JOINED; Genomic_DNA.
DR   EMBL; M74784; AAA91743.1; JOINED; Genomic_DNA.
DR   EMBL; M74785; AAA91743.1; JOINED; Genomic_DNA.
DR   EMBL; M74786; AAA91743.1; JOINED; Genomic_DNA.
DR   EMBL; M74787; AAA91743.1; JOINED; Genomic_DNA.
DR   EMBL; M74788; AAA91743.1; JOINED; Genomic_DNA.
DR   EMBL; M74790; AAA91743.1; JOINED; Genomic_DNA.
DR   EMBL; M74791; AAA91743.1; JOINED; Genomic_DNA.
DR   EMBL; AC165340; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS21115.1; -. [P20917-2]
DR   CCDS; CCDS90207.1; -. [P20917-1]
DR   PIR; B33785; B33785.
DR   RefSeq; NP_001333013.1; NM_001346084.1. [P20917-1]
DR   RefSeq; NP_001333014.1; NM_001346085.1. [P20917-1]
DR   RefSeq; NP_001333015.1; NM_001346086.1. [P20917-2]
DR   RefSeq; NP_001333016.1; NM_001346087.1. [P20917-2]
DR   RefSeq; NP_001333017.1; NM_001346088.1. [P20917-2]
DR   RefSeq; NP_034888.1; NM_010758.3. [P20917-2]
DR   RefSeq; XP_006539653.1; XM_006539590.2.
DR   RefSeq; XP_006539654.1; XM_006539591.3.
DR   RefSeq; XP_011248740.1; XM_011250438.2.
DR   RefSeq; XP_011248741.1; XM_011250439.2. [P20917-1]
DR   RefSeq; XP_011248742.1; XM_011250440.2. [P20917-1]
DR   RefSeq; XP_011248743.1; XM_011250441.2.
DR   RefSeq; XP_017177496.1; XM_017322007.1. [P20917-1]
DR   RefSeq; XP_017177497.1; XM_017322008.1.
DR   PDB; 5LF5; X-ray; 3.80 A; A=20-508.
DR   PDB; 5LFR; X-ray; 2.12 A; A/B=20-325.
DR   PDB; 5LFU; X-ray; 4.30 A; A=20-508.
DR   PDB; 5LFV; X-ray; 2.30 A; A/B=20-325.
DR   PDB; 6GZJ; X-ray; 1.98 A; B=573-627.
DR   PDB; 6GZL; X-ray; 1.95 A; B=605-621.
DR   PDBsum; 5LF5; -.
DR   PDBsum; 5LFR; -.
DR   PDBsum; 5LFU; -.
DR   PDBsum; 5LFV; -.
DR   PDBsum; 6GZJ; -.
DR   PDBsum; 6GZL; -.
DR   AlphaFoldDB; P20917; -.
DR   SASBDB; P20917; -.
DR   SMR; P20917; -.
DR   BioGRID; 201285; 7.
DR   IntAct; P20917; 2.
DR   MINT; P20917; -.
DR   STRING; 10090.ENSMUSP00000139881; -.
DR   ChEMBL; CHEMBL1250416; -.
DR   UniLectin; P20917; -.
DR   GlyConnect; 2446; 2 N-Linked glycans (1 site). [P20917-2]
DR   GlyConnect; 2519; 13 N-Linked glycans (1 site).
DR   GlyGen; P20917; 9 sites, 13 N-linked glycans (1 site).
DR   iPTMnet; P20917; -.
DR   PhosphoSitePlus; P20917; -.
DR   SwissPalm; P20917; -.
DR   MaxQB; P20917; -.
DR   PaxDb; P20917; -.
DR   PeptideAtlas; P20917; -.
DR   PRIDE; P20917; -.
DR   ProteomicsDB; 287299; -. [P20917-1]
DR   ProteomicsDB; 287300; -. [P20917-2]
DR   ProteomicsDB; 312561; -.
DR   ABCD; P20917; 19 sequenced antibodies.
DR   Antibodypedia; 1364; 403 antibodies from 39 providers.
DR   DNASU; 17136; -.
DR   Ensembl; ENSMUST00000040548; ENSMUSP00000041464; ENSMUSG00000036634. [P20917-2]
DR   Ensembl; ENSMUST00000187137; ENSMUSP00000139564; ENSMUSG00000036634. [P20917-2]
DR   Ensembl; ENSMUST00000191081; ENSMUSP00000139881; ENSMUSG00000036634. [P20917-1]
DR   GeneID; 17136; -.
DR   KEGG; mmu:17136; -.
DR   UCSC; uc009ghb.1; mouse. [P20917-2]
DR   CTD; 4099; -.
DR   MGI; MGI:96912; Mag.
DR   VEuPathDB; HostDB:ENSMUSG00000036634; -.
DR   eggNOG; KOG4475; Eukaryota.
DR   GeneTree; ENSGT01040000240433; -.
DR   HOGENOM; CLU_020480_1_0_1; -.
DR   InParanoid; P20917; -.
DR   OMA; EIMDITP; -.
DR   OrthoDB; 415025at2759; -.
DR   PhylomeDB; P20917; -.
DR   TreeFam; TF332441; -.
DR   Reactome; R-MMU-193634; Axonal growth inhibition (RHOA activation).
DR   Reactome; R-MMU-210991; Basigin interactions.
DR   BioGRID-ORCS; 17136; 1 hit in 73 CRISPR screens.
DR   PRO; PR:P20917; -.
DR   Proteomes; UP000000589; Chromosome 7.
DR   RNAct; P20917; protein.
DR   Bgee; ENSMUSG00000036634; Expressed in cerebellar nuclear complex and 108 other tissues.
DR   ExpressionAtlas; P20917; baseline and differential.
DR   Genevisible; P20917; MM.
DR   GO; GO:0043218; C:compact myelin; ISO:MGI.
DR   GO; GO:0005737; C:cytoplasm; ISO:MGI.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IEA:UniProtKB-SubCell.
DR   GO; GO:0097453; C:mesaxon; ISO:MGI.
DR   GO; GO:0043209; C:myelin sheath; IDA:MGI.
DR   GO; GO:0035749; C:myelin sheath adaxonal region; IDA:MGI.
DR   GO; GO:0033270; C:paranode region of axon; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; ISS:UniProtKB.
DR   GO; GO:0043220; C:Schmidt-Lanterman incisure; IDA:BHF-UCL.
DR   GO; GO:0030246; F:carbohydrate binding; IEA:UniProtKB-KW.
DR   GO; GO:1905576; F:ganglioside GT1b binding; IMP:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; ISO:MGI.
DR   GO; GO:0033691; F:sialic acid binding; IDA:UniProtKB.
DR   GO; GO:0005102; F:signaling receptor binding; ISO:MGI.
DR   GO; GO:0031103; P:axon regeneration; IGI:MGI.
DR   GO; GO:0007155; P:cell adhesion; ISS:UniProtKB.
DR   GO; GO:0098742; P:cell-cell adhesion via plasma-membrane adhesion molecules; ISS:UniProtKB.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0032289; P:central nervous system myelin formation; IGI:MGI.
DR   GO; GO:0022010; P:central nervous system myelination; IMP:UniProtKB.
DR   GO; GO:0042552; P:myelination; IMP:MGI.
DR   GO; GO:0030517; P:negative regulation of axon extension; ISS:UniProtKB.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IMP:UniProtKB.
DR   GO; GO:0045665; P:negative regulation of neuron differentiation; ISO:MGI.
DR   GO; GO:0010977; P:negative regulation of neuron projection development; IMP:UniProtKB.
DR   GO; GO:0048711; P:positive regulation of astrocyte differentiation; ISO:MGI.
DR   GO; GO:0031643; P:positive regulation of myelination; IMP:CACAO.
DR   GO; GO:0019226; P:transmission of nerve impulse; IMP:MGI.
DR   Gene3D; 2.60.40.10; -; 4.
DR   InterPro; IPR013162; CD80_C2-set.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   Pfam; PF08205; C2-set_2; 1.
DR   SMART; SM00409; IG; 4.
DR   SMART; SM00408; IGc2; 2.
DR   SUPFAM; SSF48726; SSF48726; 4.
DR   PROSITE; PS50835; IG_LIKE; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell adhesion; Cell membrane;
KW   Direct protein sequencing; Disulfide bond; Glycoprotein;
KW   Immunoglobulin domain; Lectin; Lipid-binding; Lipoprotein; Membrane;
KW   Palmitate; Phosphoprotein; Reference proteome; Repeat; Signal;
KW   Transmembrane; Transmembrane helix; Ubl conjugation.
FT   SIGNAL          1..19
FT   CHAIN           20..627
FT                   /note="Myelin-associated glycoprotein"
FT                   /id="PRO_0000014857"
FT   TOPO_DOM        20..516
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        517..536
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        537..627
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          22..120
FT                   /note="Ig-like V-type"
FT   DOMAIN          139..237
FT                   /note="Ig-like C2-type 1"
FT   DOMAIN          241..325
FT                   /note="Ig-like C2-type 2"
FT   DOMAIN          327..412
FT                   /note="Ig-like C2-type 3"
FT   DOMAIN          413..508
FT                   /note="Ig-like C2-type 4"
FT   REGION          20..325
FT                   /note="Interaction with RTN4R and RTN4RL2"
FT                   /evidence="ECO:0000250|UniProtKB:P07722"
FT   REGION          578..627
FT                   /note="Required for normal axon myelination in the central
FT                   nervous system"
FT                   /evidence="ECO:0000269|PubMed:9482783"
FT   BINDING         65..67
FT                   /ligand="ganglioside GT1b (d18:1(4E))"
FT                   /ligand_id="ChEBI:CHEBI:78452"
FT                   /evidence="ECO:0000269|PubMed:27922006"
FT   BINDING         118
FT                   /ligand="ganglioside GT1b (d18:1(4E))"
FT                   /ligand_id="ChEBI:CHEBI:78452"
FT                   /evidence="ECO:0000269|PubMed:27922006"
FT   BINDING         124..128
FT                   /ligand="ganglioside GT1b (d18:1(4E))"
FT                   /ligand_id="ChEBI:CHEBI:78452"
FT                   /evidence="ECO:0000269|PubMed:27922006"
FT   MOD_RES         545
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P07722"
FT   MOD_RES         547
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P07722"
FT   MOD_RES         549
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P07722"
FT   MOD_RES         591
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   LIPID           531
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250|UniProtKB:P07722"
FT   CARBOHYD        22
FT                   /note="C-linked (Man) tryptophan"
FT                   /evidence="ECO:0000269|PubMed:27922006"
FT   CARBOHYD        99
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:27922006"
FT   CARBOHYD        223
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:27922006"
FT   CARBOHYD        246
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:27922006"
FT   CARBOHYD        315
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:27922006"
FT   CARBOHYD        332
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:27922006"
FT   CARBOHYD        406
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:27922006"
FT   CARBOHYD        450
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:27922006"
FT   CARBOHYD        454
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:27922006"
FT   DISULFID        37..165
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:27922006"
FT   DISULFID        42..100
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:27922006"
FT   DISULFID        159..217
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:27922006"
FT   DISULFID        261..305
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:27922006"
FT   DISULFID        347..392
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:27922006"
FT   DISULFID        421..430
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:27922006"
FT   DISULFID        432..488
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:27922006"
FT   VAR_SEQ         574..582
FT                   /note="EKQRLGSER -> REVSTRDCH (in isoform S-MAG)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_002527"
FT   VAR_SEQ         583..627
FT                   /note="Missing (in isoform S-MAG)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_002528"
FT   MUTAGEN         25
FT                   /note="W->Q: Abolishes C-linked mannosylation."
FT                   /evidence="ECO:0000269|PubMed:27922006"
FT   MUTAGEN         65
FT                   /note="Y->A: Decreases ganglioside binding."
FT                   /evidence="ECO:0000269|PubMed:27922006"
FT   MUTAGEN         118..120
FT                   /note="RGD->KGE: Abolishes protection against axon
FT                   degeneration."
FT                   /evidence="ECO:0000269|PubMed:19158290"
FT   MUTAGEN         118
FT                   /note="R->A: Abolishes ganglioside binding."
FT                   /evidence="ECO:0000269|PubMed:27922006"
FT   MUTAGEN         127
FT                   /note="Y->A: Abolishes ganglioside binding."
FT                   /evidence="ECO:0000269|PubMed:27922006"
FT   MUTAGEN         128
FT                   /note="T->A: Abolishes ganglioside binding."
FT                   /evidence="ECO:0000269|PubMed:27922006"
FT   MUTAGEN         406
FT                   /note="N->Q: Increases homodimerization."
FT                   /evidence="ECO:0000269|PubMed:27922006"
FT   MUTAGEN         473
FT                   /note="I->E: Abolishes homodimerization."
FT                   /evidence="ECO:0000269|PubMed:27922006"
FT   STRAND          22..25
FT                   /evidence="ECO:0007829|PDB:5LFR"
FT   STRAND          28..33
FT                   /evidence="ECO:0007829|PDB:5LFR"
FT   STRAND          38..40
FT                   /evidence="ECO:0007829|PDB:5LFR"
FT   STRAND          43..45
FT                   /evidence="ECO:0007829|PDB:5LFR"
FT   HELIX           48..50
FT                   /evidence="ECO:0007829|PDB:5LFV"
FT   STRAND          56..62
FT                   /evidence="ECO:0007829|PDB:5LFR"
FT   STRAND          72..75
FT                   /evidence="ECO:0007829|PDB:5LFR"
FT   TURN            76..78
FT                   /evidence="ECO:0007829|PDB:5LFR"
FT   HELIX           83..85
FT                   /evidence="ECO:0007829|PDB:5LFR"
FT   TURN            86..88
FT                   /evidence="ECO:0007829|PDB:5LFR"
FT   STRAND          89..91
FT                   /evidence="ECO:0007829|PDB:5LFR"
FT   HELIX           95..97
FT                   /evidence="ECO:0007829|PDB:5LFR"
FT   STRAND          102..104
FT                   /evidence="ECO:0007829|PDB:5LFR"
FT   HELIX           109..111
FT                   /evidence="ECO:0007829|PDB:5LFR"
FT   STRAND          113..120
FT                   /evidence="ECO:0007829|PDB:5LFR"
FT   STRAND          126..128
FT                   /evidence="ECO:0007829|PDB:5LFR"
FT   STRAND          133..140
FT                   /evidence="ECO:0007829|PDB:5LFR"
FT   STRAND          142..144
FT                   /evidence="ECO:0007829|PDB:5LFR"
FT   STRAND          155..162
FT                   /evidence="ECO:0007829|PDB:5LFR"
FT   STRAND          171..176
FT                   /evidence="ECO:0007829|PDB:5LFR"
FT   HELIX           178..180
FT                   /evidence="ECO:0007829|PDB:5LFR"
FT   STRAND          184..190
FT                   /evidence="ECO:0007829|PDB:5LFR"
FT   HELIX           192..194
FT                   /evidence="ECO:0007829|PDB:5LFR"
FT   STRAND          196..204
FT                   /evidence="ECO:0007829|PDB:5LFR"
FT   HELIX           208..210
FT                   /evidence="ECO:0007829|PDB:5LFR"
FT   STRAND          214..220
FT                   /evidence="ECO:0007829|PDB:5LFR"
FT   STRAND          227..233
FT                   /evidence="ECO:0007829|PDB:5LFR"
FT   STRAND          236..245
FT                   /evidence="ECO:0007829|PDB:5LFR"
FT   STRAND          248..252
FT                   /evidence="ECO:0007829|PDB:5LFR"
FT   STRAND          257..267
FT                   /evidence="ECO:0007829|PDB:5LFR"
FT   STRAND          270..275
FT                   /evidence="ECO:0007829|PDB:5LFR"
FT   STRAND          278..292
FT                   /evidence="ECO:0007829|PDB:5LFR"
FT   HELIX           297..299
FT                   /evidence="ECO:0007829|PDB:5LFR"
FT   STRAND          301..309
FT                   /evidence="ECO:0007829|PDB:5LFR"
FT   STRAND          312..324
FT                   /evidence="ECO:0007829|PDB:5LFR"
FT   STRAND          608..614
FT                   /evidence="ECO:0007829|PDB:6GZL"
SQ   SEQUENCE   627 AA;  69388 MW;  54E7D53096010905 CRC64;
     MIFLATLPLF WIMISASRGG HWGAWMPSTI SAFEGTCVSI PCRFDFPDEL RPAVVHGVWY
     FNSPYPKNYP PVVFKSRTQV VHESFQGRSR LLGDLGLRNC TLLLSTLSPE LGGKYYFRGD
     LGGYNQYTFS EHSVLDIVNT PNIVVPPEVV AGTEVEVSCM VPDNCPELRP ELSWLGHEGL
     GEPTVLGRLR EDEGTWVQVS LLHFVPTREA NGHRLGCQAA FPNTTLQFEG YASLDVKYPP
     VIVEMNSSVE AIEGSHVSLL CGADSNPPPL LTWMRDGMVL REAVAKSLYL DLEEVTPGED
     GVYACLAENA YGQDNRTVEL SVMYAPWKPT VNGTVVAVEG ETVSILCSTQ SNPDPILTIF
     KEKQILATVI YESQLQLELP AVTPEDDGEY WCVAENQYGQ RATAFNLSVE FAPIILLESH
     CAAARDTVQC LCVVKSNPEP SVAFELPSRN VTVNETEREF VYSERSGLLL TSILTIRGQA
     QAPPRVICTS RNLYGTQSLE LPFQGAHRLM WAKIGPVGAV VAFAILIAIV CYITQTRRKK
     NVTESSSFSG GDNPHVLYSP EFRISGAPDK YESEKQRLGS ERRLLGLRGE SPELDLSYSH
     SDLGKRPTKD SYTLTEELAE YAEIRVK
//
